DBVT Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of -- compared to DBV Technologies SA's net margin of 46.57%. DBV Technologies SA's return on equity of -- beat Cellectis SA's return on equity of -31.46%.

DBV Technologies SA has a consensus price target of $22.63, signalling upside risk potential of 185.08%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 305.59%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.080, which suggesting that the stock is 108.034% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.219, suggesting its more volatile than the S&P 500 by 221.86%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $12.7M. DBV Technologies SA's net income of -$23M is lower than Cellectis SA's net income of $5.9M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 3.39x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to DBV Technologies SA's net margin of -9.55%. DBV Technologies SA's return on equity of -- beat Edap TMS SA's return on equity of -39.5%.

DBV Technologies SA has a consensus price target of $22.63, signalling upside risk potential of 185.08%. On the other hand Edap TMS SA has an analysts' consensus of $8.50 which suggests that it could grow by 548.86%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.080, which suggesting that the stock is 108.034% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.124, suggesting its less volatile than the S&P 500 by 87.615%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $21.7M. DBV Technologies SA's net income of -$23M is lower than Edap TMS SA's net income of -$2.1M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 0.71x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -- beat Genfit SA's return on equity of --.

DBV Technologies SA has a consensus price target of $22.63, signalling upside risk potential of 185.08%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 200.01%. Given that Genfit SA has higher upside potential than DBV Technologies SA, analysts believe Genfit SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.080, which suggesting that the stock is 108.034% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.243%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. DBV Technologies SA's net income of -$23M is higher than Genfit SA's net income of --. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 5.83x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -- compared to DBV Technologies SA's net margin of -31.41%. DBV Technologies SA's return on equity of -- beat Trinity Biotech PLC's return on equity of --.

DBV Technologies SA has a consensus price target of $22.63, signalling upside risk potential of 185.08%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 2677.78%. Given that Trinity Biotech PLC has higher upside potential than DBV Technologies SA, analysts believe Trinity Biotech PLC is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.080, which suggesting that the stock is 108.034% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 1.210, suggesting its more volatile than the S&P 500 by 20.986%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Trinity Biotech PLC quarterly revenues of $15.2M. DBV Technologies SA's net income of -$23M is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 0.10x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.